Homologous recombination deficiency, high tumor mutation burden and microsatellite instability-high disease also appeared more common in the KRAS wild-type population.In addition, early-onset pancreatic cancers — those diagnosed before age 50 years — appeared more likely to be KRAS wild-type, exhibit homologous recombination deficiency phenotype and have germline BRCA1/BRCA2 alterations. Read more . . .
Potentially targetable oncogenic rearrangements are more prevalent among patients with KRAS wild-type pancreatic cancer than those with KRAS-mutated disease, according to study results presented at ASCO Annual Meeting.